Oppenheimer maintained a Perform rating on Intuitive Surgical shares (NASDAQ:ISRG), following the company's release of its fourth-quarter results for 2024. The medical device company, currently valued ...

Lee Hambright, an analyst from Bernstein, maintained the Buy rating on Intuitive Surgical (ISRG – Research Report). The associated price target ...

Intuitive Surgical (NASDAQ:ISRG – Get Free Report) had its target price raised by stock analysts at Raymond James from ...

In a report released today, Patrick Wood from Morgan Stanley maintained a Buy rating on Intuitive Surgical (ISRG – Research Report), with a ...

Presentation Operator Good day, and thank you for standing-by. Welcome to the Q4 2024 Intuitive Earnings Conference Call. At ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.

Intuitive Surgical reports Q4 2024 revenue of $2.41 ... the adoption by customers of the Company’s products; and the goals it shares with its customers, including improving patient outcomes.

Vertex Pharmaceuticals is an innovative powerhouse with a good stock to buy on the dip. You can look at the momentum for some stocks and have a feeling that it's about to end. Others, though, have ...

Fourth quarter 2024 GAAP net income attributable to Intuitive was $686 million, or $1.88 per diluted share, compared with $606 million, or $1.69 per diluted share, in the fourth quarter of 2023.

Intuitive (Nasdaq: ISRG) + Intuitive Surgical Inc. $602.149 1.60% Open 589.728 Day High 596.241 52 Week High 468.78 52 Week ...

Intuitive Surgical Inc (ISRG) reports strong financial performance with significant revenue and net income growth, while ...